02/05/2024  09:30:08 Var. - Volume Denaro21:58:00 Lettera21:58:00 Capitalizzazione di mercato Dividend Y. Rapporto P/E
41.800EUR - 2
Fatturato: 83.600
41.000Quantità in denaro: 30 42.000Quantità in lettera: 280 1.62 bill.EUR 0.10% -

Descrizione business

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Dr. Michael Ramroth
Consiglio di amministrazione
Ainhoa Mendizabal Zubiaga, Peter Janssen, Dr. Jörg Schüttrumpf
Consiglio di sorveglianza
Dr. Bernhard Ehmer, David Bell, Uta Kemmerich-Keil, Jürgen Heilmann, Dirk Schuck, Raimon Grifols Roura
 

Dati aziendali

Name: Biotest AG
Indirizzo: Landsteinerstraße 5,D-63303 Dreieich
Telefono: +49-6103-801-0
Fax: +49-6103-801-150
E-mail: mail@biotest.de
Internet: www.biotest.de
Industria: Healthcare
Settore: Medical Products
Sub settore: Advanced Medical Devices
Fine dell'anno finanziario: 31/12
Flottante libero: 100.00%
Data dell'IPO: 14/10/1987

Rapporti con gli investitori

Name: Dr. Monika Buttkereit
IR telefono: +49-6103-801-4406
IR Fax: +49-6103-801-347
IR e-mail: investor_relations@biotest.de

Company calendar

CW 19 | 07/05/2024 General Shareholder Meeting
CW 19 | 07/05/2024 Interim Report 1st Quarter/3 Months
CW 19 | 08/05/2024 Ex-Dividend
CW 20 | 13/05/2024 Dividend Payment
CW 31 | 30/07/2024 Interim Report 2nd Quarter/6 Months
 

Principali azionisti

Grifols S.A.
 
96.00%
Freefloat
 
4.00%